Economic evaluation of bevacizumab in the treatment of non-small cell lung cancer (NSCLC).
Economic evaluation of bevacizumab in the treatment of non-small cell lung cancer (NSCLC).
复制标题
DOI：
10.2147/ceor.s27770
复制
发表时间：
2012
期刊：
影响因子：
--
通讯作者：
Shih YC
中科院分区：
文献类型：
--
作者：
Chien CR;Shih YC
提供负担得起的癌症护理变得越来越重要。贝伐单抗（BEV）是一种昂贵的分子靶向药物，对包括肺癌在内的多种癌症有效。本综述的目的是评估已发表的BEV治疗非小细胞肺癌（NSCLC）的经济学评价。在PubMed、科克伦和卫生技术评估报告中检索了2012年2月之前的英文出版物。研究由两名评审员独立筛选，8篇出版物被纳入审查。对这8篇文章的结果进行了列表，所有成本估计均以2011年美元报告。在这8篇文章中，3篇是成本研究，5篇是成本效果/效用分析。对于一线治疗，一项研究报告称含BEV方案是最昂贵的方案，但另一项研究报告称与培美曲塞/顺铂相比可节省成本。与其他方案相比，两项成本效益研究报告含BEV方案具有成本效益（增量成本效益比[ICER]在30，318 - 54，317美元/生命年范围内），但其他三项研究报告不具有成本效益（ICER超过300，000美元/生命年）。在对BEV治疗NSCLC的经济学评价进行综述时，发现文献对BEV的经济效益尚无定论。BEV在NSCLC其他治疗环境中的作用尚不清楚。进一步的研究，如具有足够把握度的临床试验，以比较低剂量和高剂量BEV之间的疗效，预测BEV生物标志物的潜在影响，以及全面的经济评价，将加强BEV在NSCLC中经济价值的现有知识。
Delivering affordable cancer care is becoming increasingly important. Bevacizumab (BEV) is a costly molecular targeted agent effective for a variety of cancer including lung cancer. The objective of this review is to assess published economic evaluation of BEV in the treatment of non-small cell lung cancer (NSCLC). A literature search in PubMed, Cochrane, and the Health Technology Assessment reports for English-language publications before February 2012 was performed. Studies were independently screened by two reviewers, and eight publications were included in the review. The results of these eight articles were tabulated and all cost estimates were reported in 2011 US dollars. Among the eight articles, three were cost studies and five were cost-effectiveness/utility analysis. For first-line treatment, BEV-containing regimen was reported to be the most costly regimen in one study but cost saving when compared with pemetrexed/cisplatin in another study. When compared with other regimens, BEV-containing regimen was reported to be cost effective in two cost-effectiveness studies (incremental cost-effectiveness ratio [ICER] in the range of US$30,318–US$54,317 per life year) but not cost effective in the other three studies (ICER over US$300,000 per life year). In this review of economic evaluation of BEV in the treatment of NSCLC, it was found that the literature was not conclusive on the economic benefit of BEV. The role of BEV in other treatment settings for NSCLC was unknown. Further studies, such as clinical trials with adequate power to compare the efficacy between low dose and high dose BEV, potential impact of predictive biomarkers for BEV, and comprehensive economic evaluation will strengthen the current state of knowledge on the economic value of BEV in NSCLC.